Recipharm moves into lyophilisation
Swedish contract pharmaceutical development and manufacturing organisation Recipharm AB is purchasing the lyophilisation facilities of Inotech Labor in Basel, Switzerland. A newly formed company, Recipharm AG, will now operate the facility.
Swedish contract pharmaceutical development and manufacturing organisation Recipharm AB is purchasing the lyophilisation facilities of Inotech Labor in Basel, Switzerland. A newly formed company, Recipharm AG, will now operate the facility.
As the facility has the capability to handle vial sizes of up to 250 litres of drug substance at a time, it can prepare materials for clinical trials and support small-scale commercial drug production. The filling equipment at the Basel plant was updated only just over a year ago; Recipharm is retaining the existing staff to manage and run the operation.
The capability to provide lyophilisation adds an important niche component to Recipharm's combined contract manufacturing and drug development and formulation expertise.
"We are very pleased to have acquired this modern lyophilisation facility from Inotech Labor as it is right in the heart of Switzerland's growing biopharmaceuticals industry where there is strong demand for this specialist technique," said Thomas Eldered, ceo and managing director, Recipharm. "Bringing lyophilisation into our service offering represents an important step in our strategic drive to expand into the realm of biologicals."